Research ArticleArticle
Open Access
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years
Ronald F. van Vollenhoven, Roy M. Fleischmann, Daniel E. Furst, Stuart Lacey and Patricia B. Lehane
The Journal of Rheumatology August 2015, jrheum.150051; DOI: https://doi.org/10.3899/jrheum.150051
Ronald F. van Vollenhoven
From the Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institute, Stockholm, Sweden; Department of Internal Medicine, University of Texas, Southwestern Medical Center, Dallas, Texas; Department of Rheumatology, University of California, Los Angeles Medical Center, Los Angeles, California, USA; Roche Products Ltd., Welwyn Garden City, UK. Sponsored and funded by F. Hoffmann-La Roche, Genentech (a member of the Roche group), and Biogen Idec. Support for third-party writing assistance for this manuscript, furnished by Vivian Chen, PharmD of Health Interactions, was funded by F. Hoffmann-La Roche Ltd. R.F. van Vollenhoven, MD, Chief of the Unit for Clinical Therapy Research, Inflammatory Disease, Karolinska Institute; R.M. Fleischmann, MD, Clinical Professor of Medicine, Department of Internal Medicine, University of Texas, Southwestern Medical Center; D.E. Furst, MD, Carl M. Pearson Professor of Medicine, Department of Rheumatology, University of California, Los Angeles Medical Center; S. Lacey, MSc, Statistician, Roche Products Ltd.; P.B. Lehane, PhD, Senior Clinical Development Scientist, Roche Products Ltd. Address correspondence to Professor R.F. van Vollenhoven, Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska University Hospital, D1:00, 17176, Stockholm, Sweden. E-mail: ronald.van.vollenhoven@ki.se. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication June 17, 2015.
Roy M. Fleischmann
From the Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institute, Stockholm, Sweden; Department of Internal Medicine, University of Texas, Southwestern Medical Center, Dallas, Texas; Department of Rheumatology, University of California, Los Angeles Medical Center, Los Angeles, California, USA; Roche Products Ltd., Welwyn Garden City, UK. Sponsored and funded by F. Hoffmann-La Roche, Genentech (a member of the Roche group), and Biogen Idec. Support for third-party writing assistance for this manuscript, furnished by Vivian Chen, PharmD of Health Interactions, was funded by F. Hoffmann-La Roche Ltd. R.F. van Vollenhoven, MD, Chief of the Unit for Clinical Therapy Research, Inflammatory Disease, Karolinska Institute; R.M. Fleischmann, MD, Clinical Professor of Medicine, Department of Internal Medicine, University of Texas, Southwestern Medical Center; D.E. Furst, MD, Carl M. Pearson Professor of Medicine, Department of Rheumatology, University of California, Los Angeles Medical Center; S. Lacey, MSc, Statistician, Roche Products Ltd.; P.B. Lehane, PhD, Senior Clinical Development Scientist, Roche Products Ltd. Address correspondence to Professor R.F. van Vollenhoven, Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska University Hospital, D1:00, 17176, Stockholm, Sweden. E-mail: ronald.van.vollenhoven@ki.se. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication June 17, 2015.
Daniel E. Furst
From the Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institute, Stockholm, Sweden; Department of Internal Medicine, University of Texas, Southwestern Medical Center, Dallas, Texas; Department of Rheumatology, University of California, Los Angeles Medical Center, Los Angeles, California, USA; Roche Products Ltd., Welwyn Garden City, UK. Sponsored and funded by F. Hoffmann-La Roche, Genentech (a member of the Roche group), and Biogen Idec. Support for third-party writing assistance for this manuscript, furnished by Vivian Chen, PharmD of Health Interactions, was funded by F. Hoffmann-La Roche Ltd. R.F. van Vollenhoven, MD, Chief of the Unit for Clinical Therapy Research, Inflammatory Disease, Karolinska Institute; R.M. Fleischmann, MD, Clinical Professor of Medicine, Department of Internal Medicine, University of Texas, Southwestern Medical Center; D.E. Furst, MD, Carl M. Pearson Professor of Medicine, Department of Rheumatology, University of California, Los Angeles Medical Center; S. Lacey, MSc, Statistician, Roche Products Ltd.; P.B. Lehane, PhD, Senior Clinical Development Scientist, Roche Products Ltd. Address correspondence to Professor R.F. van Vollenhoven, Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska University Hospital, D1:00, 17176, Stockholm, Sweden. E-mail: ronald.van.vollenhoven@ki.se. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication June 17, 2015.
Stuart Lacey
From the Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institute, Stockholm, Sweden; Department of Internal Medicine, University of Texas, Southwestern Medical Center, Dallas, Texas; Department of Rheumatology, University of California, Los Angeles Medical Center, Los Angeles, California, USA; Roche Products Ltd., Welwyn Garden City, UK. Sponsored and funded by F. Hoffmann-La Roche, Genentech (a member of the Roche group), and Biogen Idec. Support for third-party writing assistance for this manuscript, furnished by Vivian Chen, PharmD of Health Interactions, was funded by F. Hoffmann-La Roche Ltd. R.F. van Vollenhoven, MD, Chief of the Unit for Clinical Therapy Research, Inflammatory Disease, Karolinska Institute; R.M. Fleischmann, MD, Clinical Professor of Medicine, Department of Internal Medicine, University of Texas, Southwestern Medical Center; D.E. Furst, MD, Carl M. Pearson Professor of Medicine, Department of Rheumatology, University of California, Los Angeles Medical Center; S. Lacey, MSc, Statistician, Roche Products Ltd.; P.B. Lehane, PhD, Senior Clinical Development Scientist, Roche Products Ltd. Address correspondence to Professor R.F. van Vollenhoven, Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska University Hospital, D1:00, 17176, Stockholm, Sweden. E-mail: ronald.van.vollenhoven@ki.se. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication June 17, 2015.
Patricia B. Lehane
From the Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institute, Stockholm, Sweden; Department of Internal Medicine, University of Texas, Southwestern Medical Center, Dallas, Texas; Department of Rheumatology, University of California, Los Angeles Medical Center, Los Angeles, California, USA; Roche Products Ltd., Welwyn Garden City, UK. Sponsored and funded by F. Hoffmann-La Roche, Genentech (a member of the Roche group), and Biogen Idec. Support for third-party writing assistance for this manuscript, furnished by Vivian Chen, PharmD of Health Interactions, was funded by F. Hoffmann-La Roche Ltd. R.F. van Vollenhoven, MD, Chief of the Unit for Clinical Therapy Research, Inflammatory Disease, Karolinska Institute; R.M. Fleischmann, MD, Clinical Professor of Medicine, Department of Internal Medicine, University of Texas, Southwestern Medical Center; D.E. Furst, MD, Carl M. Pearson Professor of Medicine, Department of Rheumatology, University of California, Los Angeles Medical Center; S. Lacey, MSc, Statistician, Roche Products Ltd.; P.B. Lehane, PhD, Senior Clinical Development Scientist, Roche Products Ltd. Address correspondence to Professor R.F. van Vollenhoven, Unit for Clinical Therapy Research, Inflammatory Diseases, The Karolinska University Hospital, D1:00, 17176, Stockholm, Sweden. E-mail: ronald.van.vollenhoven@ki.se. Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication June 17, 2015.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years
Ronald F. van Vollenhoven, Roy M. Fleischmann, Daniel E. Furst, Stuart Lacey, Patricia B. Lehane
The Journal of Rheumatology Aug 2015, jrheum.150051; DOI: 10.3899/jrheum.150051